GGrantIndex
← Search

METFORMIN AND GLYBURIDE COMBINATION PRODUCTS IN DIABETES PATIENTS

$0M01FY2000RRNIH

Washington University, Saint Louis MO

Investigators

Linked publications & trials

Abstract

Administration of a metformin/glyburide combination tablet for 16 weeks to subjects with NIDDM who failed glycemic control on maximum dose sulfonylurea therapy will produce reductions in HbA and in fasting plasma glucose when compared to treatment with metformin alone or to glyburide (substituted for 1st or 2nd generation sulfonylurea therapy during lead-in) alone.

View original record on NIH RePORTER →